UK PPRS Overhaul
Initial views on the UK Office of Fair Trading Report.
Pharmafocus March 2007 (Volume 9, Issue 3)
It seems incredible that after 17 months and presumably some significant public cost, the OFT report into the workings of the PPRS and to British drug pricing is so extraordinarily misconstrued.
I find it also rather surprising that in the media discussions on Tuesday 20 February, the day the report was released, this fundamental flaw was picked up by neither the ABPI nor many other commentators. There are some very interesting and attractive suggestions in the OFT report for how drugs should in future be priced and reimbursed in the UK, but the report chooses to ignore the very significant role played by the currently decentralised structure of the NHS.
That the OFT is somehow linking a potential £500m saving in NHS drug expenditure with a revised way of determining drug prices in the UK is clearly misrepresenting the political and structural status of the NHS today.
Over the past 10 years the government has decentralised more and more decision making within the NHS. Centrally we have the PPRS and NICE, but fundamentally it is the regional and local Trusts that decide which drugs to use and, in the case of hospitals, how much to pay for them. If doctors are prescribing more expensive brands than either ‘equivalent’ generics or alternative cheaper brands (as the OFT report claims), this has very little to do with the PPRS and everything to do with the particular Trust’s formulary policy.
The OFT says manufacturers’ list prices are too high, and that the prices themselves do not reflect actual patient value, but surely, as most readers will be all too familiar with, regional and local payers simply will not fund medications deemed too expensive through the structures which are already in place.
It is therefore extremely interesting that the OFT says nought regarding Trusts’ difficulties in prescribing efficiently and instead chooses to effectively blame the pharma industry for too high prices on certain drugs offering marginal benefits.
The Double Whammy
What is even more worrying (is the ABPI listening?) is that what is being presented here by the OFT is a double whammy that could prove disastrous for pharmaceutical sales in the UK. It seems the OFT is recommending that the government could adopt a system of a two-stage pricing & reimbursement process of free pricing followed by a maximum national reimbursed price being determined - they say rapidly - by a committee. In addition, a form of periodic internal reference pricing based on setting maximum reimbursed prices referring to the prices of like-drugs is also recommended.
The double whammy is that the drug prices will potentially be capped at the national level before the products are launched, and then companies will still find market access difficult due to cash-strapped local and regional payers not being able to afford them. The only sensible way such a system could be introduced (apart from giving Trusts bigger drug budgets) is to either slash drug prices or in effect to introduce national formulary guidelines as to which drugs should be used and when, which is 180º different to the current decentralised approach to decision making in the NHS. If adopted, this would indeed be a very radical departure from the current landscape but it does seem to be the inevitable solution that the OFT is favouring.
NICE’s role
The OFT has proposed that NICE, the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG) all play a central role in helping to decide on reimbursement prices. But there seems to be a serious lack of clarity in these proposals, and some worryingly complicated suggested arrangements.
The OFT suggests that these bodies should effectively operate in tandem with a DH pricing unit as a single new National reimbursement committee responsible for assessing all new medications. But for various reasons, it recommends that each body’s individual and territorial authority should be retained.
According to the OFT’s recommendation, manufacturers are to negotiate prices (and potentially rebates or risk-sharing) with the DH in the light of the economic appraisal carried out by the NICE/SMC/AWMSG assessor. An appeals system has also been advocated for cases where manufacturer/DoH agreements cannot be made.
The OFT suggests that as a longer term solution (date not provided), the National reimbursement committee should become an official single body, initially designated the Commission on the Value of Medicines (CVM) and ultimately as the Medicines Pricing Commission (MPC). In the CVM the DH will still be responsible for agreeing prices with manufacturers whereas the MPC would be independent of government.
How the New System should be introduced
In theory the pharmaceutical industry should have little to fear from the introduction of internal reference pricing (IRP) or a National reimbursement committee in the UK if either were managed fairly, transparently and efficiently.
Having a National reimbursement committee could indeed be a positive development as it would finally overcome the continued inequities of postcode prescribing and also significantly reduce the need to use copious quantities of both time and shoe leather to make separate business cases to each Trust for each new innovation. However, the benefits and efficiencies could only really be made if this national reimbursement process replaces the current decentralised one, otherwise all that will happen is duplication and more confusion and regional/local disparities.
Similarly with IRP, it makes good sense to cap reimbursed prices for like medicines, be they generic or branded, as long as innovations are still able to be rewarded with better prices. The difficulty, as seen in many of the countries using IRP, is how this is measured – how much additional benefit does this triptan or that statin offer over the earlier ones? The OFT seem to recognise this and they themselves appear to favour the National reimbursement committee approach.
I think we would all agree with the OFT’s tenet that drugs offering good value should be used ahead of those offering less value, but I believe that the processes and structures are already in place to ensure that this should happen and if it is not happening (that £500m saving again), then questions should be asked of the various NHS and Department of Health stakeholders rather than looking at the PPRS and the process for drug list price-setting, which is arguably an unrelated issue, although I agree that it is linked.
Replacing the PPRS with a National reimbursement committee as a means of controlling UK-wide pharmaceutical expenditure would be a very welcome development as long as it is done fairly and replaces the cumbersome decentralised decision-making approach that we have in the NHS today.
Adam Barak
Publications
TESTIMONIALS
“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”
Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.
“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”
Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma
“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals